<p>For intravenous infusion only. Do not administer as an intravenous push or bolus.<br />
<br />
<strong>HER2 testing</strong>: Perform using FDA-approved tests by laboratories with demonstrated proficiency.<br />
<br />
The initial Pertuzumab dose is 840 mg administered as a 60-minute intravenous infusion, followed every 3 weeks thereafter by 420 mg administered as a 30 to 60 minute intravenous infusion.<br />
<br />
<strong>MBC</strong>: Administer Pertuzumab, trastuzumab, and docetaxel by intravenous infusion every 3 weeks.&nbsp;<br />
<br />
<strong>Neoadjuvant</strong>: Administer Pertuzumab, trastuzumab, and chemotherapy by intravenous infusion preoperatively every 3 weeks for 3 to 6 cycles.<br />
<br />
<strong>Adjuvant</strong>: Administer Pertuzumab, trastuzumab, and chemotherapy by intravenous infusion postoperatively every 3 weeks for a total of 1 year (up to 18 cycles).</p>